Nasal Polyps Treatment Market to Surpass US$ 5,088.90 Mn by 2030 - Coherent Market Insights

Global Nasal Polyps Treatment Market, by Drug Class, (Corticosteroids, (Nasal corticosteroids, Fluticasone, Budesonide, Mometasone, Triamcinolone, Others - Beclomethasone, Ciclesonide, etc.), Oral/Injectable Corticosteroids (Prednisone, Combination), Antibiotics, Antihistamines, Interleukin Inhibitors, (Dupilumab, Others (IL 10, IL 25 etc.)), Monoclonal Antibodies, (Mepolizumab, Omalizumab, Others), Others (Aspirin, anticholinergic agent and etc.)), by Route of Administration (Nasal, Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,992.21 Million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Market players are engaged in clinical trials for testing the effectiveness of news drugs for the treatment of nasal polyps, which is expected to drive growth of global nasal polyps treatment market, over the forecast period. For instance, on March 11, 2019, Hoffmann-La Roche, a health care company, completed its Phase III study. The study was carried out to test efficacy and safety of omalizumab compared with placebo in adult participants with chronic rhinosinusitis with nasal polyps who have had an insufficient response to standard treatments. Members received omalizumab dose from 75 mg up to 600 mg as a subcutaneous injection once every 2 weeks or once every 4 weeks.

Recommendation from regulatory bodies for approval of the new drug used in the treatment of nasal polyps, which is expected to drive growth of global nasal polyps treatment market, over the forecast period. For instance, on June 26, 2020, Novartis, a pharmaceutical corporation, got positive view recommending the approval of its product Xolair. Xolair is a supplementary treatment with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps. Xolair is the treatment for nasal polyps targeting and blocking immunoglobulin E (IgE), which helps to decrease the size of nasal polyps.

Global Nasal Polyps Treatment Market - Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to drive growth of the global nasal polyps treatment market over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases are decreasing after July 27, 2022. Therefore, as of July 27, 2022, around 572 million cases and over 6.39 million deaths have been reported.

Increasing enrollment of regulatory bodies for development of new drugs for the treatment of nasal polyps is expected to drive growth of the global nasal polys treatment market over the forecast period. For instance, on March 14, 2022, The U.S. Food and Drug Administration (FDA) has issued an update regarding the supplemental Biologics License Application for Fasenra (benralizumab) for patients with incompetently controlled chronic rhinosinusitis with nasal polyps. The U.S. FDA requested more clinical data from AstraZeneca, a pharmaceutical and biotechnology company and AstraZeneca is working closely on it to bring fasenra to patients with chronic rhinosinusitis with nasal polyps.

Browse 58 Market Data Tables and 64 Figures spread through 520 Pages and in-depth TOC on Global Nasal Polyps Treatment Market, by Drug Class, (Corticosteroids, (Nasal corticosteroids, Fluticasone, Budesonide, Mometasone, Triamcinolone, Others - Beclomethasone, Ciclesonide, etc.), Oral/Injectable Corticosteroids (Prednisone, Combination), Antibiotics, Antihistamines, Interleukin Inhibitors, (Dupilumab, Others (IL 10, IL 25 etc.)), Monoclonal Antibodies, (Mepolizumab, Omalizumab, Others), Others (Aspirin, anticholinergic agent and etc.)), by Route of Administration (Nasal, Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global nasal polyps treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/nasal-polyps-treatment-market-2775

Market players are conducting clinical trials in collaboration, in order to develop new drugs for the treatment of nasal polyps. This is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For Instance, in July, 2018, Safoni, a pharmaceutical and healthcare company in collaboration with Regeneron Pharmaceuticals, a biotechnology company, completed phase III clinical trial, conducted to estimate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray in sinking nasal congestion harshness and endoscopic nasal polyp score in participants with bilateral nasal polyposis.

Key Takeaways of the Small Molecule Injectable Drugs Market:

• Global nasal polyps treatment market is expected to exhibit a CAGR of 6.9% over the forecast period (2022-2030), owing to growth in potential markets, especially in Europe. While North America accounted for the major market share.
• New guidelines from regulatory bodies for the development of new drugs for the treatment of chronic rhinosinusitis with nasal polyps is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, in December 2021, Center for Drug Evaluation and Research had issued guidance to the industries for the development of new drugs for the treatment of Chronic Rhinosinusitis with Nasal Polyps. The guidance helped key players in the development of drugs or biological products for the treatment of chronic rhinosinusitis with nasal polyps. The guidance addresses US Food and Drug Administration’s (FDA) current recommendations regarding trial population, design, effectiveness, statistical analysis, and safety for drugs being developed for the treatment of chronic rhinosinusitis with nasal polyps

Major players operating in the global nasal polyps treatment market include Regeneron Pharmaceuticals, Inc., Hoffmann-La Roche Ag, Fougera Pharmaceuticals Inc., Novartis International Ag, Sanofi S.A., GlaxoSmithKline Plc, Intersect Ent, Dohme Corp, Merck & Co., Inc., Sanofi S.A., Norton Waterford Ltd, Astrazeneca Plc, Taro Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Limited, and OptiNose Inc.